AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. | Imfinzi is ...
AstraZeneca's treatment for adults with muscle-invasive bladder cancer was approved in the U.S.
AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...
6d
Discover Magazine on MSNNew Tuberculosis Vaccine Shows Promise to Treat Bladder CancerLearn more about the role of Tuberculosis in cancer and how a simple vaccine supports the immune system to fight it.
The FDA approved neoadjuvant Imfinzi, gemcitabine and cisplatin, followed by adjuvant Imfinzi after radical cystectomy in ...
Eddie Jordan, the Formula 1 legend, died on Thursday in Cape Town, South Africa following a journey with bladder cancer, ...
Hosted on MSN8d
Second TB vaccination boosts immunity in bladder cancer patients and reduces cancer recurrence, pilot study suggestsNon-muscle invasive bladder cancer is an early-stage cancer that affects the lining of the bladder and has not progressed ...
Bladder cancer spreads at different speeds depending on the type of bladder cancer you have. Urothelial bladder cancer is slow to spread, while other types are much faster. Urothelial bladder ...
Leveraging the power of AI and machine learning technologies, researchers at Weill Cornell Medicine developed a more ...
10d
The Independent on MSNWhat are the symptoms of prostate cancer and how common is it?What are the symptoms of prostate cancer and how common is it? - Formula One team owner Eddie Jordan has died from the ...
AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the ...
Approval of Imfinzi marks the first and only perioperative immunotherapy indicated for muscle-invasive bladder cancer.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results